Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), launched an expanded service offering at its dedicated advanced therapies site in Stevenage, UK. This enhancement introduces a new lentiviral vector manufacturing (LVV) toolbox, complementing the company’s existing adeno-associated viral (AAV) vector services. The expanded capabilities offer a comprehensive suite of services in the advanced therapy landscape.
 
LVVs are becoming increasingly prominent in the advanced therapy space across a wide range of therapeutic applications. Gene transfer using LVVs has been applied to treat several genetic diseases, such as beta-thalassemia. Lentiviral vectors have also been used to modify T-cells by introducing genes to generate immunity against cancer. Rentschler has enhanced it capabilities to serve the demand of therapeutic developers who utilize LVVs for gene modulation, including cell therapies, with the addition of lentiviral vector manufacturing to its portfolio.
 
Rentschler Biopharma’s advanced therapies facility offers customized services designed to help clients accelerate their viral vector programs at every stage – featuring toolboxes for AAVs and LVVs that are license-free. Rentschler also offers royalty-free, proprietary HEK293 cell line for advanced therapy projects. 
 
Robert Panting, General Manager, ATMP, said, “The new lentiviral vector manufacturing toolbox highlights our commitment to providing cutting-edge solutions that enable our clients to advance their viral vector programs from pre-clinical and clinical development to market. By integrating lentiviral vector process development and manufacturing to our services, we are better serving the market by meeting the growing needs of the evolving and vibrant global advanced therapies sector.”